Tandem Diabetes Care (TNDM) Depreciation & Amortization (CF) (2013 - 2026)

Tandem Diabetes Care (TNDM) has 14 years of Depreciation & Amortization (CF) data on file, last reported at $4.5 million in Q1 2026.

• Quarterly Depreciation & Amortization (CF) rose 4.48% year-over-year to $4.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.9 million (up 5.83% YoY) and the FY2025 annual result came in at $17.7 million, up 6.38% from the prior year.
• Depreciation & Amortization (CF) was little changed at $4.5 million in Q1 2026, from $4.5 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $4.5 million in Q1 2026 to a low of $3.4 million in Q1 2023.
• A 5-year average of $4.0 million and a median of $4.1 million in 2024 frame the typical range for Depreciation & Amortization (CF).
• The widest YoY moves for Depreciation & Amortization (CF): up 20.04% in 2023, down 6.39% in 2023.
• Tracing TNDM's Depreciation & Amortization (CF) over 5 years: stood at $3.6 million in 2022, then climbed by 10.71% to $4.0 million in 2023, then grew by 5.31% to $4.2 million in 2024, then rose by 5.89% to $4.5 million in 2025, then increased by 0.2% to $4.5 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $4.5 million (Q1 2026), $4.5 million (Q4 2025), and $4.5 million (Q3 2025), per Business Quant data.